Request Trial
preto-perola-shutterstock-com-1
Preto Perola / Shutterstock.com
12 November 2015Big PharmaDuncan Ribbons and Maeve Lynch

CRISPR: the shifting sands of patentability

CRISPR/Cas9 (clustered regularly interspaced short palindromic repeat/CRISPR-associated protein 9) technology is a revolutionary method of modifying genomic sequences. Although genomic modification has been possible for many years, CRISPR technology is cheaper, easier and more accurate than the modification tools preceding it.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
The clinical trial dilemma: Navigating European practice
27 November 2025   Clinical trials create a patent paradox. With EPO case law rapidly reshaping the 'expectation of success' test—most recently T136/24—the line between innovation and obviousness is blurred. Amanda Simons of J A Kemp offers drafting strategies to secure protection for your downstream innovations.
Big Pharma
Report reveals surge of AI adoption in IP but lawyers remain cautious
20 November 2025   A new report from Clarivate highlights a jump in the tech’s adoption among IP professionals over the past two years, as well as concerns over governance.
Big Pharma
Sun Pharma and BMS lead 2025 ANDA litigation
10 November 2025   According to new research, generic and brand-name pharma companies are ramping up ANDA litigation with Sun Pharma and Bristol Myers Squibb leading the charge.


Editor's picks

SCOTUS shuts the door on Entresto ‘after-arising technology’ review
Americas
SCOTUS shuts the door on Entresto ‘after-arising technology’ review
17 December 2025

Editor's picks

Americas
SCOTUS shuts the door on Entresto ‘after-arising technology’ review
17 December 2025

More features

UPC: A review of 2025 and what to expect in 2026
Mental health in IP: ‘We have a clear picture of the problem’
From Edwards to Insulet: Three key medical device cases of 2025
Edwards v Meril: Behind the UPC’s landmark medtech showdown
EU unveils sweeping pharma, biotech, and medical device reforms
Mirum targets generics in quartet of suits over liver treatment
WATCH: Clinical trials and their impact on patentability in Europe
Edwards v Meril: 3 insights from the UPC Court of Appeal’s decision